CT-868
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
Carmot Therapeutics, Inc · Phase 1 · Completed · Enrollment 32
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| CT-868 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
| Victoza | n/r | n/r | n/r | n/r |
Not shown
- CT-868: endpoint not reported
- Placebo: endpoint not reported
- Victoza: endpoint not reported